ChiCTR2100050422 版本V1.4 版本创建时间2022/04/30 11:59:24 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100050422 

最近更新日期:

Date of Last Refreshed on:

2022-03-22 13:53:40 

注册时间:

Date of Registration:

2021-08-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

单纯肌少症与合并骨质疏松患者的表观遗传学差异分析

Public title:

Analysis of epigenetic differences between patients with simple sarcopenia and patients complicated with osteoporosis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

单纯肌少症与合并骨质疏松患者的表观遗传学差异分析

Scientific title:

Analysis of epigenetic differences between patients with simple sarcopenia and patients complicated with osteoporosis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

郭立成 

研究负责人:

徐杰 

Applicant:

Guo Licheng 

Study leader:

Xu Jie 

申请注册联系人电话:

Applicant telephone:

+86 13107639506

研究负责人电话:

Study leader's telephone:

+86 13950481734

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jxht1306@sina.com

研究负责人电子邮件:

Study leader's E-mail:

jiexud@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福建省福州市东街134号

研究负责人通讯地址:

福建省福州市东街134号

Applicant address:

134 Dong Street, Fuzhou, Fujian

Study leader's address:

134 Dong Street, Fuzhou, Fujian

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

福建省立医院

Applicant's institution:

Fujian Provincial Hospital

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

K2021-05-037

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

福建省立医院伦理委员会

Name of the ethic committee:

Fujian Provincial Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2021-05-27 00:00:00

伦理委员会联系人:

练发扬

Contact Name of the ethic committee:

Lian Fayang

伦理委员会联系地址:

福建省福州市东街134号

Contact Address of the ethic committee:

134 Dong Street, Fuzhou, Fujian

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

福建省立医院

Primary sponsor:

Fujian Provincial Hospital

研究实施负责(组长)单位地址:

福建省福州市东街134号

Primary sponsor's address:

134 Dong Street, Fuzhou, Fujian

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建

市(区县):

福州

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建省立医院

具体地址:

东街134号

Institution
hospital:

Fujian Provincial Hospital

Address:

134 Dong Street

经费或物资来源:

自筹经费物资

Source(s) of funding:

Self-funded

Target disease:

sarcopenia

Target disease code:

研究类型:

病因学/相关因素研究

Study type:

Cause/Relative factors study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

本研究拟通过对单纯肌少症与合并骨质疏松患者的表观遗传学差异分析,来明确骨质疏松患者、肌少症患者与正常人群之间在遗传基因方面的差异性。  

Objectives of Study:

This study intends to analyze the epigenetic differences between patients with simple sarcopenia and patients complicated with osteoporosis, in order to clarify the genetic differences between patients with osteoporosis, sarcopenia and normal population.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.拟行腰椎开放手术的患者;
2.术前行双能X线检查;
3.获得患者或监护人知情同意。

Inclusion criteria

1. Patients who are going to undergo open lumbar spine surgery;
2. Preoperative dual energy X-ray examination;
3. Obtain informed consent from patients or guardians.

排除标准:

1.既往基础陈旧性疾病造成肢体活动受限者;
2.孕妇或哺乳期妇女;
3.无法耐受或无法配合研究者。

Exclusion criteria:

1. Patients with limited physical activity caused by previous underlying old diseases;
2. Pregnant or lactating patients;
3. Can not tolerate or cooperate with the researcher.

研究实施时间:

Study execute time:

From 2021-09-01 00:00:00 To 2023-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-09-01 00:00:00 To 2023-06-30 00:00:00  

干预措施:

Interventions:

组别:

单纯肌少症组

样本量:

2

Group:

sarcopenia group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

肌少症合并骨质疏松症

样本量:

2

Group:

osteoporosis and sarcopenia

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

正常对照组

样本量:

2

Group:

normal control group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建 

市(区县):

福州 

Country:

China 

Province:

Fujian 

City:

Fuzhou 

单位(医院):

福建省立医院 

单位级别:

三甲 

Institution
hospital:

Fujian Provincial Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

基因测序

指标类型:

主要指标

Outcome:

Gene sequencing

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

肌肉

组织:

Sample Name:

Muscle

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非项目组成员采用简单随机法,入组时将受试者分为实验组和对照组

Randomization Procedure (please state who generates the random number sequence and by what method):

The non-project team members used a simple randomized method. The subjects were divided into test group and control group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2024年9月1日;福建医科大学研究生毕业论文收录

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

September 1, 2024; Collected graduate thesis of Fujian Medical University

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理由两部分组成,一为病例记录表,二为电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

(Case Record Form, CRF)and (Electronic Data Capture, EDC)

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-08-27 12:22:21